Drug Shortage Record

Drug shortage information is not formally documented. Pharmacists learn about shortages through word of mouth, vendor phone calls, or discovering empty shelves during dispensing. There is no organizational record of which drugs are in shortage, why, or what alternatives are being used. Each pharmacist deals with shortages independently based on personal knowledge.

None — AI cannot predict shortage impact, recommend therapeutic alternatives, or forecast supply recovery because no formal drug shortage records exist.

Drug shortages are tracked in spreadsheets or informal lists maintained by the purchasing team. Records note the drug name and that it is in shortage, but documentation of shortage severity, expected resolution timeline, approved alternatives, and conservation protocols varies by who created the entry. There is no consistent format for shortage documentation across the pharmacy.

AI can display a list of drugs currently in shortage, but cannot assess shortage severity, predict resolution timelines, or systematically recommend alternatives because shortage records lack standardized severity classifications and alternative documentation.

Drug shortage records follow a standardized format: affected drug with NDC, shortage severity level, root cause category (manufacturing, raw material, demand surge, regulatory), estimated resolution timeline, approved therapeutic alternatives ranked by clinical equivalence, and conservation protocols. Every shortage is documented the same way. But shortage records are standalone documents — not linked to formulary entries, patient medication records, or supply chain purchasing history.

AI can classify shortage severity, recommend approved alternatives, and communicate conservation protocols from standardized records. Cannot assess patient-level impact, calculate institutional consumption exposure, or predict supply chain recovery because shortage records are not connected to operational systems.

Drug shortage records connect to operational context. Each shortage links to affected formulary entries (showing how many preparations use the ingredient), patient records (identifying patients currently prescribed the shortage drug), historical consumption data (quantifying institutional exposure), and supplier contract terms (revealing supply chain dependencies). A pharmacist can query 'show me all patients affected by the current propofol shortage and their viable alternatives based on clinical indication.'

AI can perform comprehensive shortage management — quantifying patient impact, calculating days of supply remaining from current inventory, recommending patient-specific alternatives based on clinical indication, and identifying supply chain concentration risks.

Drug shortage records are schema-driven entities with full relational modeling. Each shortage links to every affected formulary entry, patient medication record, supplier relationship, regulatory communication (FDA shortage notifications), and institutional consumption pattern. An AI agent can navigate from any shortage to the complete clinical, financial, and supply chain impact assessment.

AI can autonomously manage drug shortages — assessing multi-dimensional impact (clinical, financial, operational), orchestrating alternative therapy transitions, monitoring supply recovery signals, and generating regulatory compliance documentation.

Drug shortage records are real-time intelligence streams. Every ASHP shortage notification, FDA communication, supplier status update, inventory depletion signal, and alternative utilization event updates the shortage profile continuously. The shortage record is a living operational dashboard, not a static document updated periodically by the purchasing team.

Fully autonomous shortage intelligence — continuously monitoring every supply chain signal, predicting emerging shortages before they impact patient care, and orchestrating proactive mitigation as a comprehensive shortage management engine.

Ceiling of the CMC framework for this dimension.